Financial Performance - The Group's revenue for the Relevant Period was $5.3 million, a decrease of $0.6 million or 10.4% compared to $5.9 million in the Previous Period[11]. - The Group's profit for the Relevant Period was $33,000, down from a profit of $166,000 in the Previous Period[11]. - The Group's gross profit for the Relevant Period was $1.23 million, down from $1.56 million in the Previous Period[15]. - The Group reported a loss before taxation of $67,000 for the Relevant Period, compared to a profit of $226,000 in the Previous Period[15]. - Revenue from external customers for Q2 2022 was $5,315,000, a decrease of 10.4% compared to $5,934,000 in Q2 2021[71][88]. - Reportable segment profit for Q2 2022 was $1,229,000, down 21.1% from $1,559,000 in Q2 2021[91]. - The Group's consolidated profit before taxation for Q2 2022 was a loss of $67,000, compared to a profit of $226,000 in Q2 2021[95]. - Basic earnings per share for Q2 2022 was less than $0.01, compared to $0.02 in Q2 2021[118]. - The Group did not declare any dividends for Q2 2022, consistent with Q2 2021[119]. - Profit for the Relevant Period was $33,000, a decrease of 80.1% against the Previous Period, primarily due to higher operating costs and changes in other income[196]. Assets and Liabilities - Total assets as of March 31, 2022, were $18.45 million, a decrease from $21.01 million as of September 30, 2021[20]. - Total equity attributable to shareholders was $16.00 million as of March 31, 2022, compared to $15.97 million as of September 30, 2021[20]. - Non-current assets amounted to $14.38 million as of March 31, 2022, slightly down from $14.62 million as of September 30, 2021[20]. - Current liabilities totaled $2.45 million as of March 31, 2022, with borrowings and lease liabilities contributing significantly[20]. - As of March 31, 2022, total equity was SGD 16,004,000, an increase from SGD 15,971,000 as of October 1, 2021[27]. - The company reported a retained earnings of SGD 2,533,000 as of March 31, 2022, up from SGD 2,500,000 on October 1, 2021[27]. - The company's share capital as of March 31, 2022, was $1,338,000, consistent with the previous period[144]. - The share premium remained stable at $6,221,000 as of March 31, 2022, unchanged from September 30, 2021[158]. Cash Flow - For Q2 2022, net cash used in operating activities was SGD (1,180,000), compared to SGD (180,000) in Q2 2021[30]. - The net decrease in cash and cash equivalents for Q2 2022 was SGD (2,759,000), down from SGD (936,000) in Q2 2021[30]. - Cash and cash equivalents at the end of the period for Q2 2022 were SGD 985,000, compared to SGD 3,012,000 in Q2 2021[30]. Expenses - Selling and distribution expenses were $711,000 for the Relevant Period, compared to $709,000 in the Previous Period[15]. - Total unallocated expenses for Q2 2022 were $1,372,000, compared to $1,479,000 in Q2 2021[95]. - The cost of inventories for Q2 2022 was $3,777,000, slightly down from $3,847,000 in Q2 2021[101]. - Short-term employee benefits for key management personnel amounted to $482,000 in Q2 2022, slightly down from $490,000 in Q2 2021, a decrease of 1.63%[193]. - Discretionary bonuses for key management personnel were $71,000 in Q2 2022, down from $77,000 in Q2 2021, representing a decline of 7.79%[193]. - Contributions to defined contribution plans were $37,000 in Q2 2022, up from $33,000 in Q2 2021, indicating an increase of 12.12%[193]. Operational Insights - The company primarily engages in supplying tissue products to corporate customers in Singapore[40]. - The group’s principal activity focuses on tissue and hygiene-related products, with performance measured based on segment revenue and gross profit[41]. - The group has adopted all new and revised IFRSs effective from October 1, 2021, with no significant impact on financial statements[36]. - The Group's non-current assets are entirely located in Singapore, where it operates[95]. - Major customers contributing over 10% of total revenue included Company A with $774,000 and Company B with $621,000 in Q2 2022[98]. Risks and Challenges - Revenue for the Relevant Period was $5.3 million, a decrease of 10.4% compared to the Previous Period due to lower orders from corporate customers influenced by COVID-19[196]. - A significant impact on operating costs was the increase in ocean freight charges, which raised the cost of products and consequently the cost of goods sold[196]. - The company countered risks related to COVID-19 by appointing external logistics service providers and stocking up on tissue products[196]. - There was no impact on the delivery of tissue products to customers during the Relevant Period[196]. - The company faced risks from vendors potentially shutting down due to COVID-19 infections at their factories[196]. - The decrease in revenue was mainly attributed to the reduced quantities of tissue products ordered by corporate customers[196]. - The company does not consider the increase in ocean freight charges to be a risk area, viewing it as a short-term consequence of COVID-19[196].
日光控股(08451) - 2022 - 中期财报